Celgene (CELG), Biogen (BIIB), and Amgen (AMGN) all have blockbuster drugs kicking in billions of revenue. But, is one better than the other at turning that cash into profit?
Teva (TEVA) is losing patent protection for its multi-billion dollar blockbuster Copaxone next year, opening the door for Mylan (MYL) to win market share with its generic version.
The S&P 500 has set new record highs recently in a broad-based rally, but some stocks have been more important in the rally than others. Find out which stocks posted the best performance last month.
The year started with a bang for Isis Pharmaceuticals with the first antisense treatment approved by the FDA in nearly 15 years. But since then, things have gone quiet -- but its stock is still climbing -- are investors right to buy?
Last week's top five performers -- three of which were biotech stocks -- had returns ranging from nearly 8% to more than 20%. What's up (besides their stock prices)?
Teva, which just lost its CEO, will soon face stiff generic competition for its top-selling drug. Should the company merge with Mylan or Valeant to save itself and compete effectively against Actavis, which has grown considerably larger over the past year?
Falling gold prices, bearish analysts, and profit-taking spoil the day for these three stocks.
A decision to put off the launch of Biogen's (BIIB) highly anticipated launch of its MS drug Tecfidera in Europe appears to have paid off, thanks to expanded patent protection.
Favorable approval news from Europe and Japan, a small-cap biotech buying drug rights, and positive preclinical results to potentially treat a deadly infectious disease are this week's must-know biotech stories.See More Articles...